
PRODUCT INFORMATION

Olcegepant

Item No. 46436

CAS Registry No.:	204697-65-4
Formal Name:	1-[3,5-dibromo-N-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]-D-tyrosyl-L-lysyl]-4-(4-pyridinyl)-piperazine
Synonyms:	BIBN 4096, BIBN 4096BS
MF:	$C_{38}H_{47}Br_2N_9O_5$
FW:	869.7
Purity:	≥95%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Olcegepant is supplied as a solid. A stock solution may be made by dissolving the olcegepant in the solvent of choice, which should be purged with an inert gas. Olcegepant is soluble (≥10 mg/ml) in DMSO.

Description

Olcegepant is a nonpeptide calcitonin gene-related peptide (CGRP) receptor antagonist (K_i = 14.4 pM).[1] It inhibits α-CGRP- or β-CGRP-induced decreases in mean arterial blood pressure (MABP) and increases in middle meningeal artery (MMA) diameter in a closed cranial window rat model of migraine.[2] Olcegepant also inhibits vasodilation induced by electrical trigeminal ganglion stimulation in marmoset facial skin (ID_{50} = ~3 µg/kg).[1] It reduces mechanical hypersensitivity in a rat model of inflammatory pain at 3 and 10 mg/kg.[3] Olcegepant decreases muscularis externa leukocyte infiltration and improves gastrointestinal motility in a mouse model of postoperative ileus.[4] It also decreases IL-6 bronchoalveolar lavage fluid (BALF) levels and recovery time to baseline weight in a mouse model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.[5]

References

1. Doods, H., Hallermayer, G., Wu, D., *et al.* Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. *Br. J. Pharmacol.* **129(3)**, 420-423 (2000).
2. Petersen, K.A., Birk, S., Doods, H., *et al.* Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. *Br. J. Pharmacol.* **143(6)**, 697-704 (2004).
3. Hirsch, S., Corradini, L., Just, S., *et al.* The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats. *Pain* **154(5)**, 700-707 (2013).
4. Glowka, T.R., Steinebach, A., Stein, K., *et al.* The novel CGRP receptor antagonist BIBN4096BS alleviates a postoperative intestinal inflammation and prevents postoperative ileus. *Neurogastroenterol. Motil.* **27(7)**, 1038-1049 (2015).
5. Rahman, S.M., Buchholz, D.W., Imbiakha, B., *et al.* Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs. *J. Virol.* **98(7)**, e0006624 (2024).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/24/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM